


IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended) An imino-azolinone-vinyl fused-benzene derivative  
or its salt according to Formula (I),



wherein A is an 5-8 membered heterocyclic group or a carbocyclic group which may be fused with an aryl, an heteroaryl, an cycloalkyl or an heterocycloalkyl;

X is S, O or  $\text{-NR}^3$ ;

Y is S or O;


$\text{R}^1$  is selected from the group ~~comprising or~~ consisting of H, CN, carboxy, acyl,  $\text{C}_1\text{-C}_6$ -alkoxy, halogen, hydroxy, acyloxy,  $\text{C}_1\text{-C}_6$ -alkyl carboxy,  $\text{C}_1\text{-C}_6$ -alkyl acyloxy,  $\text{C}_1\text{-C}_6$ -alkyl alkoxy, alkoxycarbonyl,  $\text{C}_1\text{-C}_6$ -alkyl alkoxycarbonyl, aminocarbonyl,  $\text{C}_1\text{-C}_6$ -alkyl aminocarbonyl, acylamino,  $\text{C}_1\text{-C}_6$ -alkyl acylamino, ureido,  $\text{C}_1\text{-C}_6$ -alkyl ureido, amino,  $\text{C}_1\text{-C}_6$ -alkyl amino, ammonium, sulfonyloxy,  $\text{C}_1\text{-C}_6$ -alkyl sulfonyloxy, sulfonyl,  $\text{C}_1\text{-C}_6$ -alkyl sulfonyl, sulfinyl,  $\text{C}_1\text{-C}_6$ -alkyl sulfinyl, sulfanyl,  $\text{C}_1\text{-C}_6$ -alkyl sulfanyl, sulfonylamino,  $\text{C}_1\text{-C}_6$ -alkyl sulfonylamino [[or]] and carbamate;

$\text{R}^2$  is selected from the group ~~comprising or~~ consisting of H, halogen, acyl, amino,  $\text{C}_1\text{-C}_6$ -alkyl,  $\text{C}_2\text{-C}_6$ -alkenyl,  $\text{C}_2\text{-C}_6$ -alkynyl,  $\text{C}_1\text{-C}_6$ -alkyl carboxy,  $\text{C}_1\text{-C}_6$ -alkyl acyl,  $\text{C}_1\text{-C}_6$ -alkyl alkoxycarbonyl,  $\text{C}_1\text{-C}_6$ -alkyl aminocarbonyl,  $\text{C}_1\text{-C}_6$ -alkyl acyloxy,  $\text{C}_1\text{-C}_6$ -alkyl acylamino,  $\text{C}_1\text{-C}_6$ -alkyl ureido,  $\text{C}_1\text{-C}_6$ -alkyl carbamate,  $\text{C}_1\text{-C}_6$ -alkyl amino,  $\text{C}_1\text{-C}_6$ -alkyl alkoxy,  $\text{C}_1\text{-C}_6$ -alkyl sulfanyl,  $\text{C}_1\text{-C}_6$ -alkyl sulfinyl,  $\text{C}_1\text{-C}_6$ -alkyl sulfonyl,  $\text{C}_1\text{-C}_6$ -alkyl sulfonylaminoaryl, aryl, heteroaryl,  $\text{C}_3\text{-C}_8$ -cycloalkyl or heterocycloalkyl,  $\text{C}_1\text{-C}_6$ -alkyl aryl,  $\text{C}_1\text{-C}_6$ -alkyl

heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl-aryl or -heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl or -heteroaryl, carboxy, cyano, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, nitro, acylamino, ureido, sulfonylamino, sulfanyl, [[or]] and sulfonyl;

G is a C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, cyano or a sulfonyl moiety;

R<sup>3</sup> is selected from the group ~~comprising or~~ consisting of H [[or]] and C<sub>1</sub>-C<sub>6</sub>-alkyl; with the proviso that the following 8 compounds are excluded :



Claim 2 (Currently Amended): The imino-azolinone-vinyl fused-benzene derivative or its salt according to claim 1, wherein A is selected from the group consisting of 2H-(benzo-1, 3-dioxolanyl), 2H, 3H-benzo-1,4-dioxanyl, 2,3-dihydrobenzofuranyl, anthraquinonyl, 2,2-difluorobenzo-1,3-dioxolenyl, 1,3-dihydrobenzofuranyl, benzofuranyl, 4-methyl-2H-benzo-1,4-oxazin-3-onyl, pyridinyl, pyrazinyl, and 4-methyl-2H, 3H-benzo-1,4-oxazinyl.

Claim 3 (Currently Amended): The imino-azolinone-vinyl fused-benzene derivative or its salt according to claim 2, wherein A is a dioxolenyl or a pyridinyl moiety.

Claim 4 (Currently Amended): The imino-azolinone-vinyl fused-benzene derivative or its salt according to ~~any of the preceding claims~~ claim 1, wherein R<sup>1</sup>, ~~and/or~~ R<sup>2</sup>, or R<sup>1</sup> and R<sup>2</sup> are H.

Claim 5 (Currently Amended): The imino-azolinone-vinyl fused-benzene derivative or its salt according to ~~any of the preceding claims~~ claim 1, wherein G is a C<sub>1</sub>-C<sub>6</sub>-alkoxy, cyano or a sulfonyl moiety.

Claim 6 (Currently Amended): The imino-azolinone-vinyl fused-benzene derivative or its salt according to ~~any of the preceding claims~~ claim 1, wherein G is a C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, or a C<sub>1</sub>-C<sub>6</sub>-alkyl aryl moiety.

Claim 7 (Currently Amended): The imino-azolinone-vinyl fused-benzene derivative or its salt according to ~~claims 1 to 5~~ claim 1, wherein G is a sulfonyl moiety of the formula –SO<sub>2</sub>-R<sup>4</sup>, ~~whereby~~ wherein R<sup>4</sup> is selected from the group ~~comprising or~~ consisting of ~~[[of]]~~ H, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl carbamate, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylaminoaryl, aryl, heteroaryl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl or heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl-aryl, ~~[[or]]~~ C<sub>2</sub>-C<sub>6</sub>-alkenyl-heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl-aryl, ~~[[or]]~~ C<sub>2</sub>-C<sub>6</sub>-alkynyl-heteroaryl, carboxy, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, acylamino, and sulfonylamino.

Claim 8 (Currently Amended): The imino-azolinone-vinyl fused-benzene derivative or its salt according to claim 7, wherein R<sup>4</sup> is aryl, heteroaryl or C<sub>1</sub>-C<sub>3</sub> alkyl.

Claim 9 (Currently Amended): The imino-azolinone-vinyl fused-benzene derivative or its salt according to ~~any of the preceding claims~~ claim 1, wherein X is S, Y is O, R<sup>1</sup> and R<sup>2</sup> are H, and A is a dioxolenyl or pyridinyl moiety.

Claim 10 (Currently Amended): The imino-azolinone-vinyl fused-benzene derivative or its salt according to claim 1 ~~any of the preceding claims~~, selected from the group consisting of :

N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-2-chloro-benzene sulfonamide;

Ethanesulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-3-chloro-benzene sulfonamide;

5-Chloro-1,3-dimethyl-1H-pyrazole-4-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

3-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidenesulfamoyl)-thiophene-2-carboxylic acid methyl ester;

6-Chloro-pyridine-3-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

Quinoline-8-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-methane sulfonamide;

N-[5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-4-oxo-thiazolidin-2-ylidene]-benzenesulfonamide;

N-[5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-4-oxo-thiazolidin-2-ylidene]-4-methyl-benzenesulfonamide;

N-[5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-4-oxo-thiazolidin-2-ylidene]-methanesulfonamide;

Biphenyl-2-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

Pyridine-3-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

3-(4-Oxo-5-quinolin-6-ylmethylene-thiazolidin-2-ylidenesulfamoyl)-thiophene-2-carboxylic acid methyl ester;

2-Chloro-N-(4-oxo-5-quinolin-6-ylmethylene-thiazolidin-2-ylidene)-benzene sulfonamide;

3-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidenesulfamoyl)-thiophene-2-carboxylic acid;

5-Benzo[1,3]dioxol-5-ylmethylene-thiazolidine-2,4-dione-2-(O-methyl-oxime);

4-oxo-5-quinoxalin-6-ylmethylene-thiazolidin-2-ylidene-cyanamide;

5-Benzo[1,3]dioxol-5-ylmethylene-2-benzylimino-thiazolidin-4-one;


2-Benzylimino-5-quinolin-6-ylmethylene-thiazolidin-4-one;

2-Propylimino-5-quinolin-6-ylmethylene-thiazolidin-4-one;

5-Benzo[1,3]dioxol-5-ylmethylene-2-propylimino-thiazolidin-4-one; and

5-(4-Dimethylamino-quinazolin-6-ylmethylene)-2-methylamino-thiazol-4-one.

Claim 11 (Currently Amended): A composition comprising a carrier, adjuvant, diluent, excipient, or a combination thereof and [[An]] an imino-azolinone-vinyl fused-benzene derivative or its salt according to Formula (I)



wherein A is an 5-8 membered heterocyclic group or an carbocyclic group which may be fused with an aryl, an heteroaryl, an cycloalkyl or an heterocycloalkyl;

X is S, O or  $-NR^3$ ;


Y is S or O;

$R^1$  is selected from the group ~~comprising or~~ consisting of H, CN, carboxy, acyl,  $C_1$ - $C_6$ -alkoxy, halogen, hydroxy, acyloxy,  $C_1$ - $C_6$ -alkyl carboxy,  $C_1$ - $C_6$ -alkyl acyloxy,  $C_1$ - $C_6$ -alkyl alkoxy, alkoxy carbonyl,  $C_1$ - $C_6$ -alkyl alkoxy carbonyl, aminocarbonyl,  $C_1$ - $C_6$ -alkyl aminocarbonyl, acylamino,  $C_1$ - $C_6$ -alkyl acylamino, ureido,  $C_1$ - $C_6$ -alkyl ureido, amino,  $C_1$ - $C_6$ -alkyl amino, ammonium, sulfonyloxy,  $C_1$ - $C_6$ -alkyl sulfonyloxy, sulfonyl,  $C_1$ - $C_6$ -alkyl sulfonyl, sulfinyl,  $C_1$ - $C_6$ -alkyl sulfinyl, sulfanyl,  $C_1$ - $C_6$ -alkyl sulfanyl, sulfonylamino,  $C_1$ - $C_6$ -alkyl sulfonylamino [[or]] and carbamate;


$R^2$  is selected from the group ~~comprising or~~ consisting of H, halogen, acyl, amino,  $C_1$ - $C_6$ -alkyl,  $C_2$ - $C_6$ -alkenyl,  $C_2$ - $C_6$ -alkynyl,  $C_1$ - $C_6$ -alkyl carboxy,  $C_1$ - $C_6$ -alkyl acyl,  $C_1$ - $C_6$ -alkyl alkoxy carbonyl,  $C_1$ - $C_6$ -alkyl aminocarbonyl,  $C_1$ - $C_6$ -alkyl acyloxy,  $C_1$ - $C_6$ -alkyl acylamino,  $C_1$ - $C_6$ -alkyl ureido,  $C_1$ - $C_6$ -alkyl carbamate,  $C_1$ - $C_6$ -alkyl amino,  $C_1$ - $C_6$ -alkyl alkoxy,  $C_1$ - $C_6$ -alkyl sulfanyl,  $C_1$ - $C_6$ -alkyl sulfinyl,  $C_1$ - $C_6$ -alkyl sulfonyl,  $C_1$ - $C_6$ -alkyl sulfonylaminoaryl, aryl, heteroaryl,  $C_3$ - $C_8$ -cycloalkyl, [[or]]  $C_3$ - $C_8$ -heterocycloalkyl,  $C_1$ - $C_6$ -alkyl aryl,  $C_1$ - $C_6$ -alkyl heteroaryl,  $C_2$ - $C_6$ -alkenyl-aryl, [[or]]  $C_2$ - $C_6$ -alkenyl-heteroaryl,  $C_2$ - $C_6$ -alkynyl aryl, [[or]]  $C_2$ - $C_6$ -alkynyl-heteroaryl, carboxy, cyano, hydroxy,  $C_1$ - $C_6$ -alkoxy, nitro, acylamino, ureido, sulfonylamino, sulfanyl, [[or]] and sulfonyl;

G is a C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, cyano or a sulfonyl moiety;

R<sup>3</sup> is selected from the group ~~comprising or~~ consisting of H ~~[[or]] and~~ C<sub>1</sub>-C<sub>6</sub>-alkyl; ~~for use as a medicament~~; with the proviso that the following 4 compounds are excluded:



Claim 12 (Currently Amended): A method of treating or preventing at least one disease in a patient in need thereof, comprising administering Use of an imino-azolinone-vinyl fused-benzene derivative or its salt according to Formula (I)



wherein A is an 5-8 membered heterocyclic group or a carbocyclic group which may be fused with an aryl, an heteroaryl, an cycloalkyl or an heterocycloalkyl;

X is S, O or -NR<sup>3</sup>;

Y is S or O;

R<sup>1</sup> is selected from the group ~~comprising or~~ consisting of H, CN, carboxy, acyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, halogen, hydroxy, acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-

C<sub>6</sub>-alkyl alkoxy, alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, ammonium, sulfonyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyloxy, sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, sulfonylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylamino ~~[[or]]~~ and carbamate;

R<sup>2</sup> is selected from the group ~~comprising or~~ consisting of H, halogen, acyl, amino, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkyl carboxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acyl, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aminocarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl acyloxy, C<sub>1</sub>-C<sub>6</sub>-alkyl acylamino, C<sub>1</sub>-C<sub>6</sub>-alkyl ureido, C<sub>1</sub>-C<sub>6</sub>-alkyl carbamate, C<sub>1</sub>-C<sub>6</sub>-alkyl amino, C<sub>1</sub>-C<sub>6</sub>-alkyl alkoxy, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfanyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfinyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonyl, C<sub>1</sub>-C<sub>6</sub>-alkyl sulfonylaminoaryl, aryl, heteroaryl, C<sub>3</sub>-C<sub>8</sub>-cycloalkyl, ~~[[or]]~~ C<sub>3</sub>-C<sub>8</sub>-heterocycloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl-aryl, ~~[[or]]~~ C<sub>2</sub>-C<sub>6</sub>-alkenyl-heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl, ~~[[or]]~~ C<sub>2</sub>-C<sub>6</sub>-alkynyl-heteroaryl, carboxy, cyano, hydroxy, C<sub>1</sub>-C<sub>6</sub>-alkoxy, nitro, acylamino, ureido, sulfonylamino, sulfanyl, ~~[[or]]~~ and sulfonyl;

G is a C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkyl aryl, C<sub>1</sub>-C<sub>6</sub>-alkyl heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkenyl-aryl or -heteroaryl, C<sub>2</sub>-C<sub>6</sub>-alkynyl aryl or -heteroaryl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, cyano, C<sub>1</sub>-C<sub>6</sub>-acyl, or a sulfonyl moiety;

R<sup>3</sup> is selected from the group comprising or consisting of H or C<sub>1</sub>-C<sub>6</sub>-alkyl;

to the patient in need thereof in an amount sufficient to treat or prevent the at least one disease; wherein the at least one disease is selected from the group consisting of  
~~for the preparation of a medicament for the prophylaxis and/or treatment of~~  
autoimmune disorders, ~~and/or~~ inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, ~~kidney diseases~~, platelet aggregation, cancer, transplantation, graft rejection, ~~[[or]] lung injuries, and a combination thereof.~~



Claim 13 (Currently Amended): ~~Use according to~~ The method of claim 12, wherein G is a C<sub>1</sub>-C<sub>6</sub>-alkoxy, cyano or a sulfonyl moiety.

Claim 14 (Currently Amended): ~~Use according to any claims 11 to 13~~ The method of claim 12, wherein the imino-azolinone-vinyl fused-benzene derivative or its salt is selected from the group consisting of:

N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-2-chloro-benzene sulfonamide;

Ethanesulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-3-chloro-benzene sulfonamide;

5-Chloro-1,3-dimethyl-1H-pyrazole-4-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

3-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidenesulfamoyl)-thiophene-2-carboxylic acid methyl ester;

6-Chloro-pyridine-3-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

Quinoline-8-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-amide;

N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-benzene sulfonamide;

N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-4-methyl-benzene sulfonamide;

N-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene)-methane  
sulfonamide;

N-[5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-4-oxo-thiazolidin-2-ylidene]-  
benzenesulfonamide;

N-[5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-4-oxo-thiazolidin-2-ylidene]-  
4-methyl-benzenesulfonamide;

N-[5-(2,2-Difluoro-benzo[1,3]dioxol-5-ylmethylene)-4-oxo-thiazolidin-2-ylidene]-  
methanesulfonamide;

Biphenyl-2-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-  
ylidene)-amide;

Pyridine-3-sulfonic acid (5-benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-  
ylidene)-amide;

3-(4-Oxo-5-quinolin-6-ylmethylene-thiazolidin-2-ylidenesulfamoyl)-thiophene-2-  
carboxylic acid methyl ester;

2-Chloro-N-(4-oxo-5-quinolin-6-ylmethylene-thiazolidin-2-ylidene)-benzene  
sulfonamide;

3-(5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidenesulfamoyl)-  
thiophene-2-carboxylic acid;

5-Benzo[1,3]dioxol-5-ylmethylene-4-oxo-thiazolidin-2-ylidene-cyanamide;

5-Benzo[1,3]dioxol-5-ylmethylene-thiazolidine-2,4-dione 2-(O-methyl-oxime);

4-Oxo-5-quinoxalin-6-ylmethylene-thiazolidin-2-ylidene-cyanamide;

5-Benzo[1,3]dioxol-5-ylmethylene-2-benzylimino-thiazolidin-4-one;

2-Benzylimino-5-quinolin-6-ylmethylene-thiazolidin-4-one;

2-Propylimino-5-quinolin-6-ylmethylene-thiazolidin-4-one;

5-Benzo[1,3]dioxol-5-ylmethylene-2-propylimino-thiazolidin-4-one; and  
5-(4-Dimethylamino-quinazolin-6-ylmethylene)-2-methylamino-thiazol-4-one.

Claim 15 (Currently Amended): ~~Use according to any of claims 12 to 14~~ The method of claim 12, wherein ~~said diseases are~~ the at least one disease is selected in the from the group consisting of ~~group including~~ multiple sclerosis, psoriasis, rheumatoid arthritis, ~~multiple sclerosis~~, systemic lupus erythematosus, inflammatory bowel disease, lung inflammation, thrombosis, ~~or brain infection/inflammation such as meningitis, [[or]]~~ encephalitis, and combinations thereof.

Claim 16 (Currently Amended): ~~Use according to any of claims 12 to 14~~ The method of claim 12, wherein ~~said~~ the at least one disease is selected from the group consisting of ~~diseases are selected in the group including~~ Alzheimer's disease, Huntington's disease, CNS trauma, stroke, ~~[[or]] ischemic conditions, and combinations thereof~~.

Claim 17 (Currently Amended): ~~Use according to any of claims 12 to 14~~ The method of claim 12, wherein the at least one disease is selected from the group consisting of ~~said diseases are selected in the group including~~ atherosclerosis, heart hypertrophy, cardiac myocyte dysfunction, elevated blood pressure, ~~[[or]] vasoconstriction, and combinations thereof~~.

Claim 18 (Currently Amended): ~~Use according to any of claims 12 to 14~~ The method of claim 12, wherein the at least one disease is selected from the group consisting

~~of said diseases are selected in the group including~~ chronic obstructive pulmonary disease, anaphylactic shock, fibrosis, psoriasis, allergic diseases, asthma, stroke, ~~[[or]]~~ ischemic conditions, ischemia-reperfusion, ~~platelets~~ platelet aggregation/activation, platelet activation, skeletal muscle atrophy/~~hypertrophy,~~ skeletal muscle hypertrophy, leukocyte recruitment in cancer tissue, angiogenesis, invasion metastasis, ~~in particular~~ melanoma, Kaposi's sarcoma, sepsis, graft rejection, glomerulo sclerosis, glomerulo nephritis, progressive renal fibrosis, endothelial injuries in the lung, ~~[[and]]~~ epithelial injuries in the lung, ~~or in general lung airways~~ airway inflammation, and combinations thereof.


Claim 19 (Currently Amended): A method of inhibiting PI3 kinase activity, comprising  
inhibiting PI3 kinase activity with the imino-azolinone-vinyl fused-benzene derivative or its salt of claim 1

~~Use according to any of claims 12 to 18 for the modulation, in particular for the inhibition, of the PI3 kinase activity.~~

Claim 20 (Currently Amended): ~~Use according to~~ The method of claim 19, wherein said PI3 kinase is a PI3 kinase  $\gamma$ .

Claim 21 (Currently Amended): A pharmaceutical composition ~~containing~~ comprising at least one thiazolidinone-vinyl fused-benzene derivative or its salt according to claim 1 ~~any of claims 1 to 10~~ and a pharmaceutically acceptable carrier, diluent, ~~[[or]]~~ excipient, or combination thereof.

Claim 22 (Currently Amended): A method of preparing a 2-imino-azolinone-  
vinyl fused-benzene ~~derivatives~~ derivative or its salt of Formula (I) according to claim 1  
~~any of claims 1 to 10~~ comprising derivatizing the imine of Formula Ia with the group G to  
form the vinyl fused-benzene derivative or its salt ~~the following step:~~



wherein ~~A, R<sup>1</sup>, R<sup>2</sup>, G, X and Y are as above defined and L is a leaving group.~~